Reporting reimbursement price decisions for onco-hematology drugs in Spain.

ABSTRACT:

Introduction

Even using well-established technology assessment processes, the basis of the decisions on drug price and reimbursement are sometimes perceived as poorly informed and sometimes may be seen as disconnected from value. The literature remains inconclusive about how Health Technology Assessment Bodies (HTAb) should report the determinants of their decisions. This study evaluates the relationship between oncology and hematology drug list prices and structured value parameters at the time of reimbursement decision in Spain.

Methods

The study includes all new onco-hematological products (22), with a first indication authorized between January 2017 and December 2019 in Spain and pricing decisions published up until October 2022. For each product, 56 contextual and non-c

SUBMITTER: Elvira D 

PROVIDER: S-EPMC10627880 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature